0001591986-22-000013.txt : 20220316 0001591986-22-000013.hdr.sgml : 20220316 20220316162303 ACCESSION NUMBER: 0001591986-22-000013 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220314 FILED AS OF DATE: 20220316 DATE AS OF CHANGE: 20220316 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Aquilo Capital, L.P. CENTRAL INDEX KEY: 0001491371 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38266 FILM NUMBER: 22745178 BUSINESS ADDRESS: STREET 1: ONE LETTERMAN DRIVE, SUITE D4900 STREET 2: BUILDING D, THE PRESIDIO CITY: SAN FRANCISCO STATE: CA ZIP: 94129 BUSINESS PHONE: (415) 635-0141 MAIL ADDRESS: STREET 1: ONE LETTERMAN DRIVE, SUITE D4900 STREET 2: BUILDING D, THE PRESIDIO CITY: SAN FRANCISCO STATE: CA ZIP: 94129 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Aquilo Capital Management, LLC CENTRAL INDEX KEY: 0001591986 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38266 FILM NUMBER: 22745179 BUSINESS ADDRESS: STREET 1: ONE LETTERMAN DRIVE STREET 2: SUITE D4900, BUILDING D CITY: SAN FRANCISCO STATE: CA ZIP: 94129 BUSINESS PHONE: 415-635-0140 MAIL ADDRESS: STREET 1: ONE LETTERMAN DRIVE STREET 2: SUITE D4900, BUILDING D CITY: SAN FRANCISCO STATE: CA ZIP: 94129 FORMER NAME: FORMER CONFORMED NAME: Aquilo Capital Managment, LLC DATE OF NAME CHANGE: 20131114 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Spero Therapeutics, Inc. CENTRAL INDEX KEY: 0001701108 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 675 MASSACHUSETTS AVENUE STREET 2: 14TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 857-242-1600 MAIL ADDRESS: STREET 1: 675 MASSACHUSETTS AVENUE STREET 2: 14TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: Spero Therapeutics, LLC DATE OF NAME CHANGE: 20170316 4 1 primary_doc.xml PRIMARY DOCUMENT X0306 4 2022-03-14 0 0001701108 Spero Therapeutics, Inc. SPRO 0001591986 Aquilo Capital Management, LLC ONE LETTERMAN DRIVE SUITE D4900, BUILDING D SAN FRANCISCO CA 94129 0 0 1 0 0001491371 Aquilo Capital, L.P. ONE LETTERMAN DRIVE, SUITE D4900 BUILDING D, THE PRESIDIO SAN FRANCISCO CA 94129 0 0 1 0 Common Stock, $0.001 par value 2022-03-14 4 P 0 15702 7.626 A 5223498 I See footnotes Common Stock, $0.001 par value 2022-03-14 4 P 0 8006 7.626 A 5231504 I See Footnotes The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of, Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. Aquilo Capital, LP only owns 3,439,140 of the 5,223,498 shares deemed to be beneficially owned by Aquilo Capital Management, LLC. Aquilo Capital, LP purchased 15,702 shares in this transaction on 3/14/2022. Aquilo Capital, LP only owns 3,439,140 of the 5,231,504 shares deemed to be beneficially owned by Aquilo Capital Management, LLC. Aquilo Capital, LP did not purchase any of the 8,006 shares purchased in this transaction on 03/14/2022. Aquilo Capital Management, LLC By: Marc Schneidman, its Managing Member, /s/ Marc Schneidman 2022-03-16 Aquilo Capital, L.P., By: Aquilo Capital Management, LLC, its General Partner By: Marc Schneidman, its Managing Member /s/ Marc Schneidman 2022-03-16